Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis

Table 2

Subgroup analyses of the relationship between ALI and OS in LC patients.

Subgroup factor	No. of cohort studies	Combined HR (95% CI)	value	Heterogeneity
				(%)
Pathological type
NSCLC	5	1.64 (1.21-2.07)	<0.001	14.2	0.329
SCLC	2	1.64 (1.24-2.05)	<0.001	0.0	0.898
Clinical stage
Metastatic	3	1.51 (1.05-1.97)	<0.001	0.0	0.609
Nonmetastatic	2	1.64 (1.24-2.05)	<0.001	0.0	0.898
Mixed	2	2.40 (1.25-3.55)	<0.001	40.2	0.196
Cut-off value
<24.23	5	1.57 (1.21-1.92)	<0.001	0.0	0.510
≥24.23	2	1.80 (1.27-2.33)	<0.001	0.0	0.351
Treatment
No surgery	5	1.58 (1.28-1.89)	<0.001	0.0	0.881
With surgery	2	2.40 (1.25-3.55)	<0.001	40.2	0.196
Follow-up
<60 m	3	1.55 (1.17-1.93)	<0.001	0.0	0.597
≥60 m	4	1.77 (1.30-2.24)	<0.001	4.7	0.369